Mechanism of Action of T-705 against Influenza Virus
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
T-705, a substituted pyrazine compound, has been found to exhibit potent anti-influenza virus activity in vitro and in vivo. In a time-of-addition study, it was indicated that T-705 targeted an early to middle stage of the viral replication cycle but had no effect on the adsorption or release stage. The anti-influenza virus activity of T-705 was attenuated by addition of purines and purine nucleosides, including adenosine, guanosine, inosine, and hypoxanthine, whereas pyrimidines did not affect its activity. T-705-4-ribofuranosyl-5′-triphosphate (T-705RTP) and T-705-4-ribofuranosyl-5′-monophosphate (T-705RMP) were detected in MDCK cells treated with T-705. T-705RTP inhibited influenza virus RNA polymerase activity in a dose-dependent and a GTP-competitive manner. Unlike ribavirin, T-705 did not have an influence on cellular DNA or RNA synthesis. Inhibition of cellular IMP dehydrogenase by T-705RMP was about 150-fold weaker than that by ribavirin monophosphate, indicating the specificity of the anti-influenza virus activity and lower level of cytotoxicity of T-705. These results suggest that T-705RTP, which is generated in infected cells, may function as a specific inhibitor of influenza virus RNA polymerase and contributes to the selective anti-influenza virus activity of T-705.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y. N., Hong, Z., Andino, R., & Cameron, C. E. (2000) · Nature Medicine · doi:10.1038/82191 · Cited by 820
Kaiser, L., Wat, C., Mills, T., Mahoney, P., Ward, P., & Hayden, F. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1667 · Cited by 501
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.977-981.2002 · Cited by 501
Self-citationStreeter, D. G., Witkowski, J. T., Khare, G. P., Sidwell, R. W., Bauer, R. J., Robins, R. K., & Simon, L. N. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.4.1174 · Cited by 478
Witkowski, J. T., Robins, R. K., Sidwell, R. W., & Simon, L. N. (1972) · Journal of Medicinal Chemistry · doi:10.1021/jm00281a014 · Cited by 471
SERIOUS MORBIDITY AND MORTALITY ASSOCIATED WITH INFLUENZA EPIDEMICS
GLEZEN, W. P. (1982) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036250 · Cited by 449
Maag, D., Castro, C., Hong, Z., & Cameron, C. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100349200 · Cited by 281
In Vitroandin VivoActivities of T-705 and Oseltamivir against Influenza Virus
Takahashi, K., Furuta, Y., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., & Shiraki, K. (2003) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020301400502 · Cited by 97
Self-citationViral Escape by Selection of Cytotoxic T Cell–Resistant Variants in Influenza a Virus Pneumonia
Price, G. E., Ou, R., Jiang, H., Huang, L., & Moskophidis, D. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.11.1853 · Cited by 97
The Immune Response to Viruses
McFarland, H. F., & Jacobson, S. (1989) · Springer eBooks · doi:10.1007/978-1-4613-1675-6_17 · Cited by 83
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Self-citationFavipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Self-citationSARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat
Zheng, J. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45053 · Cited by 1,025
Antiviral agents active against influenza A viruses
De Clercq, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2175 · Cited by 668
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2019) · Viruses · doi:10.3390/v11040326 · Cited by 622
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Shiraki, K., & Daikoku, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107512 · Cited by 573
Self-citationOestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., & Günther, S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.02.014 · Cited by 493
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
Furuta, Y., Takahashi, K., Shiraki, K., Sakamoto, K., Smee, D. F., Barnard, D. L., Gowen, B. B., Julander, J. G., & Morrey, J. D. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.02.198 · Cited by 471
Self-citationFavipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
Du, Y., & Chen, X. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1844 · Cited by 418
Continuing challenges in influenza
Webster, R. G., & Govorkova, E. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12462 · Cited by 399
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
Delang, L., Abdelnabi, R., & Neyts, J. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.03.003 · Cited by 388
Influenza virus resistance to neuraminidase inhibitors
Samson, M., Pizzorno, A., Abed, Y., & Boivin, G. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.03.014 · Cited by 343
Influenza and antiviral resistance: an overview
Lampejo, T. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03840-9 · Cited by 342
The mechanism of resistance to favipiravir in influenza
Goldhill, D. H., te Velthuis, A. J. W., Fletcher, R. A., Langat, P., Zambon, M., Lackenby, A., & Barclay, W. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811345115 · Cited by 298
Current status of potential therapeutic candidates for the COVID-19 crisis
Zhang, J., Xie, B., & Hashimoto, K. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.046 · Cited by 283
Jin, Z., Smith, L. K., Rajwanshi, V. K., Kim, B., & Deval, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068347 · Cited by 268
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Tompa, D. R., Immanuel, A., Srikanth, S., & Kadhirvel, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.076 · Cited by 257
Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?
Hayden, F. (2009) · Clinical Infectious Diseases · doi:10.1086/591851 · Cited by 256
Pandemic and seasonal influenza: therapeutic challenges
Memoli, M. J., Morens, D. M., & Taubenberger, J. K. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.03.024 · Cited by 51
Metadata
- Authors
- Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., & Shiraki, K.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2005-03
- Volume
- 49
- Issue
- 3
- Pages
- 981-986
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2138274210
- Cited by
- 546
- References
- 12
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.